590 related articles for article (PubMed ID: 29544992)
1. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.
Scorletti E; Byrne CD
Mol Aspects Med; 2018 Dec; 64():135-146. PubMed ID: 29544992
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
Kelley NS
Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
[TBL] [Abstract][Full Text] [Related]
3. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
[TBL] [Abstract][Full Text] [Related]
4. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
[TBL] [Abstract][Full Text] [Related]
5. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD.
Nobili V; Alisi A; Musso G; Scorletti E; Calder PC; Byrne CD
Crit Rev Clin Lab Sci; 2016; 53(2):106-20. PubMed ID: 26463349
[TBL] [Abstract][Full Text] [Related]
6. Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
Suzuki-Kemuriyama N; Matsuzaka T; Kuba M; Ohno H; Han SI; Takeuchi Y; Isaka M; Kobayashi K; Iwasaki H; Yatoh S; Suzuki H; Miyajima K; Nakae D; Yahagi N; Nakagawa Y; Sone H; Yamada N; Shimano H
PLoS One; 2016; 11(6):e0157580. PubMed ID: 27333187
[TBL] [Abstract][Full Text] [Related]
7. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease.
Scorletti E; Byrne CD
Annu Rev Nutr; 2013; 33():231-48. PubMed ID: 23862644
[TBL] [Abstract][Full Text] [Related]
8. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease.
Di Minno MN; Russolillo A; Lupoli R; Ambrosino P; Di Minno A; Tarantino G
World J Gastroenterol; 2012 Nov; 18(41):5839-47. PubMed ID: 23139599
[TBL] [Abstract][Full Text] [Related]
9. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.
Nogueira MA; Oliveira CP; Ferreira Alves VA; Stefano JT; Rodrigues LS; Torrinhas RS; Cogliati B; Barbeiro H; Carrilho FJ; Waitzberg DL
Clin Nutr; 2016 Jun; 35(3):578-86. PubMed ID: 26047766
[TBL] [Abstract][Full Text] [Related]
11. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
12. [A Future Perspective on the Involvement of n-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis].
Nakamoto K; Obata T; Hirasawa A; Kim KI; Kim SR; Tokuyama S
Yakugaku Zasshi; 2016; 136(4):583-9. PubMed ID: 27040343
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.
Pawlak M; Lefebvre P; Staels B
J Hepatol; 2015 Mar; 62(3):720-33. PubMed ID: 25450203
[TBL] [Abstract][Full Text] [Related]
14. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
Singh S; Arora RR; Singh M; Khosla S
Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
[TBL] [Abstract][Full Text] [Related]
15. Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.
Hodson L; Bhatia L; Scorletti E; Smith DE; Jackson NC; Shojaee-Moradie F; Umpleby M; Calder PC; Byrne CD
Eur J Clin Nutr; 2017 Aug; 71(8):973-979. PubMed ID: 28294174
[TBL] [Abstract][Full Text] [Related]
16. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
17. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial.
Janczyk W; Socha P; Lebensztejn D; Wierzbicka A; Mazur A; Neuhoff-Murawska J; Matusik P
BMC Pediatr; 2013 May; 13():85. PubMed ID: 23702094
[TBL] [Abstract][Full Text] [Related]
18. A review of the studies on food-derived factors which regulate energy metabolism via the modulation of lipid-sensing nuclear receptors.
Goto T
Biosci Biotechnol Biochem; 2019 Apr; 83(4):579-588. PubMed ID: 30572788
[TBL] [Abstract][Full Text] [Related]
19. Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease.
Valenzuela R; Ortiz M; Hernández-Rodas MC; Echeverría F; Videla LA
Curr Med Chem; 2020; 27(31):5250-5272. PubMed ID: 30968772
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
